Clinical Safety of Drug Eluting Stents in Korea Acute Myocardial Infarction Registry
1Chonbuk National University, Jeongju, Korea (Republic of); 2Chonnam National University Hospital, Gwangju, Korea (Republic of); 3Kyungpook National University Hospital, Daegu, Korea (Republic of); 4Keimyung University Hospital, Daegu, Korea (Republic of); 5Yeungnam University Hospital, Daegu, Korea (Republic of); 6Chungnam National University Hospital, Daejeon, Korea (Republic of); 7Pusan National University Hospital, Busan, Korea (Republic of); 8Jeongju Christial Hospital, Jeongju, Korea (Republic of); 9Chungbuk National University Hospital, Cheongju, Korea (Republic of); 10Keonyang University Hospital, Daejeon, Korea (Republic of); 11Korea University Hospital, Seoul, Korea (Republic of); 12Kyunehee University Hospital, Seoul, Korea (Republic of); 13Yonsei University Hospital, Seoul, Korea (Republic of); 14Asan Medical Center, Seoul, Korea (Republic of)
Background: Percutaneous coronary intervention (PCI) by drug-eluting stents (DES) may be useful in patients with acute myocardial infarction (AMI), however safety issue should be solved. This study was undertaken to know the incidence of major adverse cardiac events (MACE) and stent thrombosis in DES implanted AMI patients at real clinical practice.
Methods: On-line registry of AMI at the web site of www.kamir.or.kr has been performed in 41 primary percutaneous coronary intervention (PCI) centers in Korea.Between November 2005 and September 2006, 1,541 patients who were implanted Cypher¢ç or Taxus¢ç stents, enrolled in Korea Acute Myocardial Infarction Registry (KAMIR) and discharged from hospital without death, were analyzed during 6-month clinical follow-up.
Results: There were two groups: group I [834 patients, 61.9¡¾11.9 years: Sirolimus-Eluting Stent (Cypher¢ç)], group II [707 patients, 62.9¡¾12.0 years: Paclitaxel-Eluting Stent (Taxus¢ç)]. One month and six months MACE were not significantly different between the two groups. There were 17 stent thrombosis but, the incidence of stent thrombosis was not significantly different between two groups (group I: group II=9 (1.1%):8 (1.1%), p=1.000). The stent type, length, number, lesion complexity and diabetes were not significant for the incidence of MACE and stent thrombosis after adjustment.
Conclusion: MACE and stent thrombosis were not different between two types of DES in KAMIR. DES can be used in patients with AMI with relatively low 6-month MACE rate.
summitMD.com
